March 27, 2018 / 12:04 PM / 9 months ago

BRIEF-Krystal Submits Investigational New Drug (Ind) Application For KB103

March 27 (Reuters) - Krystal Biotech Inc:

* KRYSTAL SUBMITS INVESTIGATIONAL NEW DRUG (IND) APPLICATION FOR KB103, TOPICAL GENE THERAPY CANDIDATE FOR DYSTROPHIC EPIDERMOLYSIS BULLOSA

* KRYSTAL BIOTECH - THERAPEUTIC CANDIDATE FORMULATED INTO A TOPICAL GEL FOR DIRECT APPLICATION ONTO SKIN Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below